These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15680780)

  • 1. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
    Kubar J; Fragaki K
    Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges and perspectives in vaccination against leishmaniasis.
    de Oliveira CI; Nascimento IP; Barral A; Soto M; Barral-Netto M
    Parasitol Int; 2009 Dec; 58(4):319-24. PubMed ID: 19698801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress towards a Leishmania vaccine.
    Tabbara KS
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines in leishmaniasis: advances in the last five years.
    Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
    Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmaniasis.
    Kedzierski L
    Hum Vaccin; 2011 Nov; 7(11):1204-14. PubMed ID: 22048116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a leishmaniasis vaccine: the importance of MPL.
    Reed SG; Coler RN; Campos-Neto A
    Expert Rev Vaccines; 2003 Apr; 2(2):239-52. PubMed ID: 12899575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmaniasis: current status of vaccine development.
    Handman E
    Clin Microbiol Rev; 2001 Apr; 14(2):229-43. PubMed ID: 11292637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs.
    Nogueira FS; Moreira MA; Borja-Cabrera GP; Santos FN; Menz I; Parra LE; Xu Z; Chu HJ; Palatnik-de-Sousa CB; Luvizotto MC
    Vaccine; 2005 Sep; 23(40):4805-10. PubMed ID: 16011864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
    Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
    Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
    Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania vaccines: progress and problems.
    Kedzierski L; Zhu Y; Handman E
    Parasitology; 2006; 133 Suppl():S87-112. PubMed ID: 17274851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
    Arora SK; Pal NS; Mujtaba S
    Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
    Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA
    Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.